Camzyos (mavacamten) / BMS - LARVOL DELTA

A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER) (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA-Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy. (PubMed, Circulation) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Mavacamten for treatment of symptomatic mid-ventricular obstruction in hypertrophic cardiomyopathy: a case report. (PubMed, Eur Heart J Case Rep) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Mavacamten (▼Camzyos) for obstructive hypertrophic cardiomyopathy. (PubMed, Drug Ther Bull) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Understanding hypertrophic cardiomyopathy and its regulation by myosin drugs. (PubMed, Protein Sci) - "Furthermore, we show that three key myosin drugs, aficamten, mavacamten, and omecamtiv, modulate the phosphate release barrier of the faulty myosin, and by this means it could repair the defects of the HCM mutant associated with fast phosphate release. Our study demonstrates the importance of using multiscale approaches for the revelation of key mechanisms of HCM disease. Furthermore, we provide further evidence of the crucial role of the rate-determining barrier in establishing the overall function of the myosin cycle."

Journal • Cardiomyopathy • Cardiovascular • Heart Failure • Hypertrophic Cardiomyopathy • MYH7

Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial. (PubMed, JACC Cardiovasc Imaging) - P3 | "In the VALOR-HCM trial, treatment with mavacamten resulted in sustained favorable cardiac remodeling, including improvement in LVOT gradients, cardiac volumes, cardiac hypertrophy, diastolic function, and markers of LA and LV strain from baseline through week 128, suggesting disease modification. These favorable changes also occurred in association with meaningful improvement in quality of life."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Annotating the X-ray diffraction pattern of vertebrate striated muscle. (PubMed, Biophys J) - "Here, we use an atomic model of the human cardiac thick filament C-zone, derived from cryo-EM in the presence of the myosin inhibitor, mavacamten, to compute objectively the contributions of myosin heads, tails, titin, and cMyBP-C to the diffraction pattern, by including/excluding these components in the calculations...The computed layer-lines account well for the experimentally determined pattern. These insights should aid future understanding of the X-ray pattern of intact muscle in different conditions such as contraction and drug treatment."

Journal • TTN

Myosin-binding protein C slows cardiac myofibril relaxation kinetics. (PubMed, J Physiol) - "Mavacamten, a myosin inhibitor, accelerated both phases of relaxation independently of cMyBP-C. Overall, we interpret our results in terms of dual cross-bridge-dependent and cross-bridge-independent mechanisms of action of cMyBP-C on cardiac relaxation."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Mavacamten in Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P=N/A | N=163 | Completed | Sponsor: Bristol-Myers Squibb

New trial • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Effect of Mavacamten on Serial Speckle-Tracking Strain in Patients with Hypertrophic Cardiomyopathy. (PubMed, J Am Soc Echocardiogr) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Mavacamten effectively reduces > 100 mmHg left ventricular outflow tract gradients As early as one week of treatment in obstructive hypertrophic cardiomyopathy. (PubMed, Int J Cardiol) - "Mavacamten effectively reduced even >100 mmHg LVOT gradients and led to significant gradient reduction already in one week. Besides favourable changes in LVOT obstruction, structural and functional echocardiographic parameters, functional capacity, and cardiac biomarkers, it also led to significant improvement in myocardial work parameters."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. (PubMed, N Engl J Med) - P3 | "Among patients with nonobstructive HCM, mavacamten did not result in a significantly greater improvement in peak oxygen uptake or decrease in symptoms than placebo. (Funded by Bristol Myers Squibb; ODYSSEY-HCM ClinicalTrials.gov number, NCT05582395.)."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Covert Transthyretin Amyloidosis Mimicking Advanced Obstructive Hypertrophic Cardiomyopathy Despite Multiple Negative 99mTc-PYP Radionuclide Scans. (PubMed, JACC Case Rep) - "TTR amyloidosis can mimic hypertrophic cardiomyopathy with left ventricular outflow tract obstruction. 99m Technetium pyrophosphate scans are useful to investigate the presence of TTR amyloid, but if suspicion persists despite negative testing, it is reasonable to perform an endomyocardial biopsy."

Journal • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access (clinicaltrials.gov) - P=N/A | N=75 | Recruiting | Sponsor: UltraSight

New trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Electrophysiologic and Anatomic Changes in Patients With oHCM on Mavacamten: 1-Year Insights From AI-ECG and Echocardiography Data. (PubMed, Mayo Clin Proc) - No abstract available

Journal • Obstructive Hypertrophic Cardiomyopathy

Real-World Observations in Obstructive Hypertrophic Cardiomyopathy Patients Treated with Mavacamten: Evidence of Favorable Disease Modification. (PubMed, J Am Heart Assoc) - "In this real-world cohort, mavacamten treatment was associated with sustained symptomatic and echocardiographic improvements, suggesting a favorable, disease-modifying impact with minimal need for SRT."

Journal • Real-world evidence • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

oHCM: Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Medical University of Vienna

New trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) summit: long-term outcomes and real-world impact on obstructive HCM (ESC-WCC 2025) - "Educate the audience on the impact of mavacamten on cardiac structure and function. This promotional symposium is intended for healthcare professionals only."

Clinical • Real-world • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy in the real world: bridging guidelines and clinical practice (ESC-WCC 2025) - "Explore current strategies for risk stratification and evidence-based approaches to prevent sudden cardiac death in HCM patients, with a focus on real-world applications. Review best practices for the long-term management and follow-up of patients with oHCM treated with mavacamten through clinical case discussions, enhancing clinical decision-making skills."

Clinical • Real-world • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Beyond the obvious: decoding the diagnostic dilemmas in hypertrophic cardiomyopathy (ESC-WCC 2025) - "Explore the critical role of echocardiography in the differential diagnosis of HCM and discuss the potential applications and benefits of AI tools in enhancing diagnostic accuracy. Review best practices for the management of symptomatic oHCM with mavacamten through clinical case discussions and understand long-term management and follow-up strategies for oHCM patients."

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

ODYSSEY-HCM: Mavacamten in nHCM (ESC-WCC 2025) - No abstract available

Cardiovascular

Echocardiographic changes in nonobstructive hypertrophic cardiomyopathy patients treated with mavacamten: A sub-study of the ODYSSEY-HCM trial (ESC-WCC 2025) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Cardiac biomarkers on mavacamten in nonobstructive HCM: Sub-study of the ODYSSEY-HCM trial (ESC-WCC 2025) - No abstract available

Biomarker • Cardiovascular • Non-obstructive Hypertrophic Cardiomyopathy

Disease modeling of restrictive cardiomyopathy to identify a new therapy (ESC-WCC 2025) - "We next examined if myosin inhibitor (MYK461) or gene therapy can rescue relaxation failure, and both remedied the relaxation defects in the iPSC-derived cardiomyocyte model...Tentative results suggested myosin inhibitor mildly rescued left ventricular relaxation and normalized ejection fraction. This study revealed the molecular mechanisms of RCM caused by TNNI3 mutation and offers a potential treatment for RCM."

Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Mavacamten real-world experience: insights from the Dutch HCM Network. (ESC-WCC 2025) - "Conclusion Mavacamten is an effective and safe therapy for oHCM in the real-world setting. CYP2C19 genotype did not influence adverse events or other effects."

Clinical • Real-world • Real-world evidence • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • CYP2C19